Risk factor
Very poor trading liquidity
Profitability factor
Very low or no dividends
About
Celon Pharma S.A. operates as a fully-integrated pharmaceutical firm, undertaking the investigation, development, production, and distribution of diverse medicinal formulations. Its business model is structured around two principal areas: generic drug offerings and innovative therapeutic solutions. The company's product line addresses a range of health challenges, including oncological conditions, neurological disorders, diabetes, and other metabolic complaints. Established in 2002, this enterprise is situated in Lomianki, Poland, and functions as a subsidiary of Glatton Sp. z o.o.
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. In particular, the stock is underpriced on P/E, of fair va
Target Price
The average target price of CLN.WA is 19.5 and suggests 3.56% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendat